Participants receiving AOD-9604 maintained stable blood glucose levels, showed no changes in insulin sensitivity, demonstrated no alterations in HbA1c, and exhibited no increased risk of hyperglycemia or diabetic complications
, 20 , 1990-2000, doi: DArcy, M
Fernndez-Checa, Liver Unit, Hospital Clnic, Centre Esther Koplowitz, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS)Centro de Investigacin Biomdica en Red de Enfermedades Hepticas y Digestivas (CIBERehd), Planta Cuarta, C/Rossell 149, Barcelona 08036, Spain e-mail: [email protected] This article was submitted to Experimental Pharmacology and Drug Discovery, a Section of the journal Frontiers in Pharmacology
Journal of Pain Research, 12 , 31473159
Summary of clinical discussion, including: Patient-reported updates or concerns